Clinical trials: Radiation Injury
Breast Cancer
Safety and Efficacy of HO/02/02 20µg vs. SoC (Aloe Vera) to Reduce Radiation Dermatitis
This is a single-center, open-label, randomized, prospective study evaluating the safety and efficacy of HO/02/02 20µg topically applied daily for 15 minutes (with gauze) on treatment fields vs.
- Trial name
- ARD (NCT01923220)
- Testing
- HO/02/02 20µg, Aloe Vera Jel
- Where
- Israel
- Volunteers
- 90 people
- Sponsor
- HealOr
Acute Radiation Syndrome
Safety and Pharmacokinetic Study of BIO 300 Capsules
This trial is designed to evaluate the safety and pharmacokinetics of BIO 300 capsules when administered orally to healthy male and female volunteers. BIO 300 is expected to be safe for use starting at 500 mg.
- Trial name
- NCT00504335
- Testing
- BIO 300 Capsules
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Humanetics Corporation
Healthy Volunteer Study
Phase 1 BIO 300 Oral Suspension
This is a two-part study of BIO 300 Oral Suspension in healthy male and female volunteers. The first part is a multiple ascending dose (MAD) study to test the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the drug…
- Trial name
- NCT06741345
- Testing
- BIO 300 Oral Suspension
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Humanetics Corporation
Radiation-induced Dermatitis
Study of ST266 Versus Saline in Treating Skin Irritation From Radiation
The objective of this study is to evaluate the safety and efficacy of ST266 in treating radiation burns of the skin in patients undergoing treatments for breast cancer and to compare ST266 treated burns with those treated with…
- Trial name
- NCT01714973
- Testing
- ST266
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion
Acute Radiation Syndrome
A Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011
This trial is designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic of KMRC011 injection in healthy adult volunteers.
- Trial name
- NCT03585803
- Where
- South Korea
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Intron Biotechnology, Inc.